Business Overview and Financial Strategy - Regeneron is leveraging genetics, proteomics, and big data to accelerate innovation and R&D productivity, with approximately 45 clinical programs across six core therapeutic areas[7] - The company is deploying capital to maximize long-term value creation through internal investment in R&D, business development, and returning capital to shareholders, with ~$6 billion committed to U S manufacturing and R&D infrastructure expansion[15, 16] - Regeneron returned ~$3.8 billion to shareholders in 2025, including ~$3.4 billion in share repurchases and ~$0.4 billion in dividends[16] - Non-GAAP R&D spend is expected to be $7 billion+ in 2026[16] Product Portfolio and Pipeline Highlights - Dupixent global net sales are growing, with Q3 2025 sales reaching $3.619 billion[10] - EYLEA HD physician demand grew 10% from Q3 to Q4 2025, and Q4 2025 U S net sales reached $1.1 billion[10] - Libtayo achieved Q3 2025 global net sales of $365 million, with a 27% worldwide year-over-year growth[14] - The company has a pipeline targeting large market opportunities, including $15B+ in ophthalmology, $55B+ in oncology, $60B+ in hematology, $15B+ in cardiovascular & metabolic diseases, $50B+ in immunology & inflammation, and $10B+ in neurology & rare diseases[23] Upcoming Milestones and Clinical Data - Phase 3 data for Olatorepatide in obesity in China is expected in 1H 2026[42] - Fianlimab + cemiplimab is expected to report results in 1L metastatic melanoma from a Phase 3 trial in 1H 2026[78] - Cemdisiran monotherapy is planned for FDA submission in Q1 2026, with a decision expected by Q4 2026/Q1 2027 for gMG[52, 77]

Core Viewpoint - Immuneering Corporation has announced a clinical supply agreement with Eli Lilly for the evaluation of atebimetinib in combination with olomorasib in a Phase 2 trial targeting advanced non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations [1][2] Group 1: Clinical Development - The agreement supports the evaluation of Immuneering's lead product candidate, atebimetinib, a novel dual MEK inhibitor, in combination with olomorasib [1] - Immuneering is also evaluating atebimetinib in combination with Regeneron's anti-PD-1 therapy Libtayo in advanced NSCLC patients [1] - The combination aims to provide a vertical blockade of the RAS-MAPK pathway, potentially improving treatment outcomes in patients with limited options [3] Group 2: Product and Pipeline - Immuneering maintains global development and commercialization rights to atebimetinib [4] - The company is developing Deep Cyclic Inhibitors, with atebimetinib designed to improve durability and tolerability for MAPK pathway-driven tumors [5] - Atebimetinib is currently in a Phase 2a trial for advanced solid tumors, including pancreatic cancer [5]

Core Viewpoint - Sensei Biotherapeutics is transitioning from early response-focused readouts to longer-term efficacy signals in its Phase 1/2 study of solnerstotug, which shows a favorable safety profile and potential for better patient adherence and outcomes [2][3] Clinical Program Highlights - Full data for the Phase 1/2 dose expansion cohort is expected by year-end 2025, with enrollment complete at 64 patients [6] - The ongoing trial evaluates solnerstotug as a monotherapy and in combination with cemiplimab in patients with advanced solid tumors [3] - Preliminary clinical data indicates favorable activity in PD-(L)1 resistant "hot" tumors, with solnerstotug well tolerated and no dose-limiting toxicities reported [6] Corporate Updates - Sensei's cash position was $28.6 million as of June 30, 2025, down from $41.3 million at the end of 2024, with expectations to fund operations into Q2 2026 [8] - Research and Development expenses decreased to $2.5 million in Q2 2025 from $4.6 million in Q2 2024, attributed to lower personnel and facility costs [9] - General and Administrative expenses also decreased to $2.7 million in Q2 2025 from $3.2 million in Q2 2024, primarily due to lower personnel costs [10] Financial Results - The net loss for Q2 2025 was $4.9 million, an improvement from a net loss of $7.1 million in Q2 2024 [10] - Total operating expenses for Q2 2025 were $5.2 million, down from $7.8 million in Q2 2024 [13]

Table of Contents As filed with the U.S. Securities and Exchange Commission on June 8, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 83-1495913 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No. ...

As filed with the U.S. Securities and Exchange Commission on April 21, 2023. Registration No. 333-269606 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 (Amendment No. 3) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 83-1495913 (I.R.S. Employer Identification No.) (State or other jurisdiction of incorporation or organization) Classification Code Number) 444 West Lake Stree ...

As filed with the U.S. Securities and Exchange Commission on April 4, 2023. Registration No. 333-269606 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 83-1495913 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identificat ...